Long-term follow up of patients with chronic HCV and no or minimal fibrosis shows low risk for liver-related morbidity and mortality after achieving SVR with DAA-based therapy: Results from the gilead SVR registry.

Authors

M BourlièreFollow
E J. Gane
I Jacobsen
Stuart C. Gordon, Henry Ford HealthFollow
M S. Sulkowski
B L. McNabb
F Chen
H Dvory-Sobol
J McNally
D M. Brainard
M Subramanian
A Ramji
S Zeuzem
K AgarwalFollow
K R. Reddy

Recommended Citation

Bourliere M, Gane EJ, Jacobson I, Gordon SC, Sulkowski MS, McNabb BL, Chen F, Dvory-Sobol H, McNally J, Brainard DM, Subramanian M, Ramji A, Zeuzem S, Agarwal K, and Reddy KR. Long-term follow up of patients with chronic HCV and no or minimal fibrosis shows low risk for liver-related morbidity and mortality after achieving svr with daa-based therapy: Results from the gilead SVR registry. Hepatology 2017; 66:518A-519A.

Document Type

Conference Proceeding

Publication Date

2017

Publication Title

Hepatol

Volume

66

First Page

518A

Last Page

519A